肺癌患者手术治疗前后SE-CAD、CA125水平的变化

目的:探讨了肺癌患者手术治疗前后血清可溶性上皮钙粘蛋白(SE-CAD)和CA125水平的变化。方法:应用放免法测定31例肺癌患者血清CA125含量,酶联法测定上皮钙粘蛋白的含量,并与30名正常健康人作比较。结果:肺癌患者在手术治疗前血清CA125和SE-CAP含量非常显著地高于正常人水平(P<0.01)。手术治疗后6个月复发者CA125、SE-CAD水平持续异常,未复发者CA125、SE-CAD水平恢复正常。结论:CA125、SE-CAD含量的变化与肺癌患者的病情和愈后密切相关,具有一定的临床实用价值。

Changes of Serum Soluble Epicyte Cadherin (SE-CAD) and CA125 Levels in Patients with Lung Cancer Operation

Objective To investigate the changes of serum SE-CAD and CA125 levels in 31 patients with lung cancer after operation. Methods Serum CA125 levels were determined with RIA and serum SE-CAD levels with ELISA in 31 patients with lung cancer both before and after operation as well as in 30 controls. Results Before operation serum CA125 and SE-CAD levels were significantly higher in the patients than those in controls (P<0.01). Twenty-one of the 28 patients underwent operation showed no sign of recurrence at 6 months and their serum CA125 and SE-CAD levels dropped to within normal range. However in the 7 patients with recurrence serum levels of CA125 and SE-CAD remained abnormally high. Conclusion Serum CA125 and SE-CAD levels were closely related to the diseases process of lung cancer and were of prognostic value.